Karuna Pharmaceuticals   Report issue

For profit Phase 3
Founded: Boston Massachusetts United States (2009)
Status: Acquired by Bristol-Myers Squibb (2023)

Organization Overview

First Clinical Trial
2016
NCT02831231
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Karuna Pharmaceuticals | Karuna Therapeutics | Karuna Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

trospium (sanctura) (10 trials)

xanomeline (13 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 2